Itrinol use at endometrial hyperplasia

Written by Hramova I.А., Slyusareva Е.Е., Kurleeva Т.Y.

  UDK: УДК 618.145-007.61-085.256.5 | Pages: 80–82 | Full text PDF | Open PDF 


Background. Currently endometrial hyperplasia refers to a group of hormone-dependent and proliferative diseases. Universal corrector of hyperplastic processes the endometrium is a metabolic drug “Indinol Forto” (intrinol). Methods. The intrinola effect on adhesion and secretory activity of the synthetic monocytes/macrophages was studied in 28 premenopausal women with glandular cystic endometrial hyperplasia (control group – 15 healthy women). Results. Women with endometrial hyperplasia revealed increasing adhesion activity of blood monocytes and peritoneal macrophages labilization of lysosomal membranes, accompanied by increased secretion and decreased of the synthesis of intracellular lysozyme. Indinol fort use as a remedy led to the regression of the disease, reduction in macrophage cell adhesive activity, the stabilization of lysosomal membranes, reduction secretion and increase of intracellular synthesis of lysozyme. Conclusions. The data expand the understanding of the mechanism of action of the drug “Indinol Forto”, which causes regression of the disease, and also makes adjustments to the immune system.

Links to authors:

I.А. Hramova1, Е.Е. Slyusareva1, Т.Y. Kurleeva2
1 Pacific State Medical University (2 Ostryakova Ave. Vladivostok 690950 Russian Federation),
2 Primorsky Regional Perinatal Center (1B Mozhaiskaya Str. Vladivostok 690011 Russian Federation)

1. Askolskaya S.I., Kogan E.A., Sagindykova R.R. The detection frequency of endometrial adenocarcinoma in patients with pre-menopausal period with preoperative diagnosis of atypical endometrial hyperplasia // Obstetrics and gynecology. 2014. No. 9. P.59–62.
2. Clinical gynecology: selected lectures / edit by V.N. Prilepskaya. М.: MEDpress-inform, 2007. 480 p.
3. Kuznetsova I.V. Possibilities of treatment of endometrial hyperplastic processes // Difficult Patient. 2010. No. 1–2. P.18–22.
4. Ozolinya L.A., Patrushev L.I., Boldina E.B. Current views on the pathogenesis of endometrial hyperplastic processes and their possible treatments // Treatment and Prevention. 2013. No. 2. P.106–112.
5. Rebrova O.Yu. Statistical analysis of medical data. The usage of software programs ‘Statistica’. М.: Media sphere, 2002. 305 p.
6. Guideline on endocrine gynecology / edited by E.M. Vikhlyaeva. М: MIA, 2006. 786p.
7. Strizhakov A.N., Kushlinskiy N.E., Shakhlamova M.N. [et al.] Differentiated approach to the diagnosis and management of patients with hyperplastic processes of the endometrium in postmenopausal women // Issues of Gynecology, Obstetrics and Perinatology. 2014. No. 1. P.5–14.
8. Freydlin I.S. Cells of the immune system: the development, activation, effector functions // Russian Immunological Journal. 1999. Vol. 4, No. 1. P. 9–15.
9. Khramova I.A. Peritoneal macrophages and reproductive system of women. Vladivostok: Medicine FE, 2015. 142 p.
10. Khramova I.A., Slyusareva E.E., Antonyuk M.V. Influence of iodine-bromine baths in the macrophage cell system of women with climacteric syndrome // Pacific Medical Journal. 2014. No. 2. P. 43–45.
11. Sharonov A.S. Phagocytes, lysosomes, membranes. Vladivostok: Dalnauka, 2007. 128 p.
12. Sheshukova N.A., Makarov I.O., Fomina M.N. Endometrial hyperplastic processes: etiopathogenesis, clinical picture, diagnosis, treatment // Obstetrics and Gynecology. 2011. No. 4. P. 16–21.
13. Mutter G.l., Baak J.P., Crum C.B. [et al.] Endometrial precancer diagnosis by histopathology clonal analyses and computerized morphometry // J. Pathol. 2001. Vol. 190, No. 4. P. 462–469.
14. Wong G.Y., Bradlow l., Sepkovic D. [et al.] Dose-ranging study of indole-3-carbinol for breast cancer prevention // J. Cell. Biochem. 1997. Suppl. 28–29. P. 111–116.


Founded in 1997  |  Editions in a year: 4, Articles in one issue: 30 |  ISSN of print version: 1609-1175  |  Ind.: 18410 (Agency "Rospechat’")  |  Edition: 1000 c.